Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database
| Autor: | Mitch DeKoven, Allan Scott, Sooyeol Lim, Kainan Sun, Vinod Dasa |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
musculoskeletal diseases
Health plan medicine.medical_specialty medicine.medical_treatment Knee replacement intra-articular Osteoarthritis outcomes research 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine knee replacement Hyaluronic acid hyaluronic acid medicine health economics In patient 030212 general & internal medicine Claims database Original Research 030203 arthritis & rheumatology Pharmacology business.industry lcsh:RM1-950 General Medicine musculoskeletal system medicine.disease lcsh:Therapeutics. Pharmacology chemistry Physical therapy Molecular Medicine Viscosupplementation Outcomes research business viscosupplementation |
| Zdroj: | Drugs in Context Drugs in Context, Pp 1-12 (2016) |
| ISSN: | 1745-1981 |
| Popis: | Background: Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis (OA) effectively reduces pain and delays total knee replacement (TKR) surgery; however, little is known about relative differences in clinical and cost outcomes among different HA products. Objective: To compare disease-specific costs and risk of TKR among patients receiving different HA treatments in a commercially insured cohort of patients with knee OA in the USA. Method: Retrospective analyses using IMS Health’s PharMetrics Plus Health Plan Claims Database were conducted by identifying knee OA patients with claims indicating initiation of HA treatment at an ‘index date’ during the selection period (2007–2010). Patients were required to be continuously enrolled in the database for 12 months preindex to 36 months postindex. A generalized linear model (GLM) with a gamma distribution and log-link function was used to model aggregate patient-based changes in disease-specific costs. A Cox proportional hazards model (PHM) was used to model the risk of TKR. Both multivariate models included covariates such as age, gender, comorbidities, and preindex healthcare costs. Results: 50,389 patients with HA treatment for knee OA were identified. 18,217 (36.2%) patients were treated with HA products indicated for five injections per treatment course (Supartz and Hyalgan). The remainder were treated with HA products indicated for fewer than five injections per treatment course, with 20,518 patients (40.7%) receiving Synvisc; 6,263 (12.4%), Euflexxa; and 5,391 (10.7%), Orthovisc. Synvisc- and Orthovisc-injected patients had greater disease-specific costs compared to Supartz/Hyalgan (9.0%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|